Cancer Diagnostics Market Size Evaluation and Growth Forecast 2026 to 2035

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Consumables (Antibodies, Probes), Instruments (Pathology Instruments, Imaging Instruments, Biopsy), Technology (IVD Testing, imaging, and biopsy technology), Application (Breast Cancer, Lung Cancer), End User (Hospitals)- Market Outlook And Industry Analysis 2035"

Global Cancer Diagnostics market Size is valued at 1USD 117.0 billion in 2025 and is predicted to reach USD 214.6 billion by the year 2035 at a 6.3% CAGR during the forecast period for 2026 to 2035.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1726

The global healthcare industry has undergone significant disruption as a result of the COVID-19 pandemic, which placed substantial strain on medical infrastructure and resources worldwide. Public health measures implemented to contain the spread of the virus adversely affected the delivery of routine healthcare services, while simultaneously driving a surge in demand for acute and emergency care. One major consequence was the widespread deferral of elective procedures, including oncology-related surgeries, as healthcare systems prioritized urgent and COVID-19-specific treatments. This shift has raised critical concerns, particularly for cancer patients, who face heightened vulnerability to infection along with increased risks of complications and mortality.

Data from the American Society of Clinical Oncology indicate that cancer care services experienced a marked decline between March and July 2020 compared to the same period in 2019. This decline was observed across multiple areas, including diagnostic biopsies, cancer screenings, outpatient consultations, therapeutic interventions, and surgical procedures.

During April 2020, at the height of the pandemic, screening activities dropped sharply, with colon cancer screenings decreasing by 75%, breast cancer screenings by 85%, lung cancer screenings by 56%, and prostate cancer screenings by 74%. Additionally, around 800 lung cancer screening appointments were canceled in March 2020 alone.

Although healthcare systems have since resumed standard screening protocols, the volume of newly screened individuals has not yet returned to pre-pandemic levels. This continued shortfall highlights the enduring impact of the pandemic on early cancer detection and diagnosis.

List of Prominent Players in the Cancer Diagnostics Market:
• Abbott Laboratories,
• Agilent Technologies Inc.,
• AMOY Diagnostics Co Ltd.,
• Astellas Pharma Inc. (Japan)
• BD
• BiocartisNV,
• bioMérieux SA (France)
• Bristol-Myers Squibb Company (U.S.)
• Cancer Diagnostics Inc.,
• Danaher Corporation,
• DiagnoCure Inc. (Canada)
• DiaSorin S.P.A.,
• Excat Science
• F. Hoffmann-La Roche Ltd.
• FUJIFILM Corporation,
• GE Healthcare
• Genomic Health, Inc. (U.S.)
• GSK plc. (U.K.)
• Hologic, Inc.
• Illumina, Inc.
• Koninklijke Philips N.V. (Philips)
• Lilly (U.S.)
• Merck KGaA, (Germany)
• Myriad Genetics Inc.,
• Novartis AG (Switzerland)
• Pfizer, Inc. (U.S.)
• Qiagen N.V.
• Quest Diagnostics Incorporated. (U.S.)
• Quidel Corporation,
• Roche Diagnostics,
• Siemens Healthcare GmbH
• Thermo Fisher Scientific, Inc.

Add our site to Google Preferred Sources for quality content: https://google.com/preferences/source?q=insightaceanalytic.com

Market Dynamics
Drivers:
The diagnostic testing market is expected to witness substantial growth, largely driven by continuous advancements in technology. For example, the introduction of the Genius Digital Diagnostics System in Europe in 2021 highlights the integration of volumetric imaging and artificial intelligence-based deep learning to enhance the detection of precancerous and cancerous cervical cells. Such innovations are anticipated to significantly support market expansion over the forecast period by improving diagnostic accuracy and efficiency.

Challenges:
In several developing and low-income countries, healthcare institutions often face budgetary limitations that restrict their ability to invest in advanced diagnostic imaging technologies. To address rising demand for diagnostic services, many facilities rely on refurbished equipment as a more economical alternative. While this approach improves accessibility, it may limit the adoption of advanced technologies, thereby constraining overall market growth and innovation.

Regional Trends:
The Asia-Pacific region is projected to experience the fastest growth during the forecast period, driven by strategic initiatives from key industry participants, the expansion of national cervical cancer screening programs, increased research and development activities, and ongoing technological advancements. For instance, the Australian Cervical Cancer Foundation launched National Cervical Cancer Awareness Week in November 2019 to raise awareness and promote preventive measures, with the objective of eliminating cervical cancer in Australia by 2035. Leading companies such as Hologic, Inc. are actively supporting such initiatives and screening programs, thereby contributing to the growth of the regional diagnostic testing market.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1726

Recent Developments:
• In November 2021, Magnetom Free was introduced by Siemens Healthineers. The Star whole-body MRI scanner was created to dramatically improve access to magnetic resonance imaging on a global scale.

Segmentation of Cancer Diagnostics Market-
By Product-
• Consumables
o Antibodies
o Kits & Reagents
o Probes
o Others
• Instruments
o Pathology based Instrument
o Slide Staining Systems
o Tissue Processing Systems
o Cell Processors
o PCR Instruments
o NGS Instruments
o Microarrays
o Other Pathology-based Instruments
o Imaging Instruments
o CT Systems
o Ultrasound Systems
o MRI Systems
o Mammography Systems
o Nuclear Imaging Systems
• Biopsy Instruments
By Technology-
• IVD Testing
o Polymerase Chain Reaction (PCR)
o In Situ Hybridization (ISH)
o Immunohistochemistry (IHC)
o Next-generation Sequencing (NGS)
o Microarrays
o Flow Cytometry
o Immunoassays
o Others
• Imaging
o Magnetic Resonance Imaging (MRI)
o Computed Tomography (CT)
o Positron Emission Tomography (PET)
o Mammography
o Ultrasound
• Biopsy Technique
By Application-
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Melanoma
• Others
By End User-
• Hospitals
• Diagnostics Laboratories
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

View Overview Report: https://www.insightaceanalytic.com/report/cancer-diagnostics-market/1726

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.